ADVENTRX Appoints Vice President of Manufacturing
April 09 2008 - 6:00AM
PR Newswire (US)
SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that it has
appointed Jose Hechavarria to the new position of vice president of
manufacturing. Mr. Hechavarria will be responsible for leading the
company's planned commercial manufacturing operations. "We are
pleased to have recruited Jose to our team," said Evan M. Levine,
ADVENTRX chief executive officer. "He brings experience and
leadership in the drug manufacturing and quality arena, and we
believe his expertise will be especially valuable as we continue to
develop the commercial manufacturing processes for both ANX-530
(vinorelbine emulsion) and ANX-514 (docetaxel emulsion)." Mr.
Hechavarria has over 30 years of experience in the pharmaceutical
industry and has overseen all aspects of third-party contract
manufacturing. He has held various senior positions at companies
including Bristol-Myers Squibb, Dupont Pharmaceuticals, DuPont
Merck Pharmaceutical Company as well as the New England Nuclear
Corporation. Mr. Hechavarria holds a B.S. in chemical technology
from the University of Lowell, an A.S. in nuclear engineering
technology from the Wentworth Institute, and has completed post
graduate training in parenteral therapeutics agents at the
University of Tennessee College of Pharmacy. About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
company focused on in-licensing, developing and commercializing
proprietary product candidates primarily for the treatment of
cancer and infectious disease. The Company seeks to improve the
performance and commercial potential of existing treatments by
addressing problems associated with these treatment regimens. More
information can be found on ADVENTRX's web site at
http://www.adventrx.com/. Forward Looking Statement ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors that, if they do not materialize or prove to be accurate,
could cause ADVENTRX's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited to: the risk that ADVENTRX will be unable to raise
sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones; the risk that
preclinical results are not indicative of the success of subsequent
clinical trials and the results of pending clinical trials; the
potential for ADVENTRX's product candidates to receive regulatory
approval for one or more indications on a timely basis or at all,
and the uncertain process of seeking regulatory approval; other
difficulties or delays in developing, testing, manufacturing,
marketing and obtaining regulatory approval for ADVENTRX's product
candidates; the potential for regulatory authorities to require
additional preclinical work or other clinical requirements to
support regulatory filings; the market potential for ADVENTRX's
product candidates and ADVENTRX's ability to compete in those
markets; the scope and validity of patent protection for ADVENTRX's
product candidates; patent and non-patent exclusivity covering
Navelbine(R) and Taxotere(R); and other risks and uncertainties
more fully described in ADVENTRX's press releases and periodic
filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are
available at http://www.sec.gov/. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date when made. ADVENTRX does not intend to revise
or update any forward-looking statement as set forth in this press
release to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,
Inc., +1-858-552-0866 Web site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024